

6. (Amended) The process as claimed in [one or more of claims 1 to] claim 5, wherein the eukaryotic potassium channel is present in a yeast expression plasmid.

7. (Amended) The process as claimed in [one or more of claims 1 to] claim 6, wherein the mutated *S. cerevisiae* cell expresses constitutively a growth reporter.

8. (Amended) The process as claimed in [one or more of claims 1 to] claim 7, wherein a substance to be tested, which has an effect on the eukaryotic potassium channel, inhibits the growth of the mutated *S. cerevisiae* cell.

9. (Amended) The process as claimed in [one or more of claims 1 to] claim 7, wherein the effect of a substance to be tested on the eukaryotic potassium channel is determined by measuring the cell count of the mutated *S. cerevisiae* cells.

14. (Amended) The mutated *S. cerevisiae* cell as claimed in [one or more of claims 11 to] claim 13, which *S. cerevisiae* cell expresses heterologously a eukaryotic potassium channel.

15. (Amended) The mutated *S. cerevisiae* cell as claimed in [one or more of claims 11 to] claim 14, wherein the eukaryotic potassium channel is a human potassium channel.

16. (Amended) The mutated *S. cerevisiae* cell as claimed in [one or more of claims 11 to] claim 15, wherein the eukaryotic potassium channel is a HERG1, Kv1.5 or gPIRK1.

17. (Amended) The mutated *S. cerevisiae* cell as claimed in [one or more of claims 11 to] claim 16, wherein the eukaryotic potassium channel is mutated.

SUB 'CS'  
B3 19. (Amended) The use of a mutated *S. cerevisiae* cell as claimed in [one or more of claims 11 to] claim 17 for identifying substances which inhibit the activity of the eukaryotic potassium channel.

22. (Amended) A test kit [comprisng] comprising a mutated *S. cerevisiae* cell as claimed in [any of claims 11 to] claim 17.

23. (Amended) A process for the preparation of a medicament, wherein

a) an inhibitor of a eukaryotic potassium channel is identified with the aid of a process as claimed in [any of claims 1 to] claim 10,

b) the inhibitor is prepared or isolated by known chemical processes, and

134 c) physiologically acceptable additives are added to the inhibitor.

24. (Amended) A process for the preparation of a medicament, wherein

a) an activator of a eukaryotic potassium channel is identified with the aid of a process as claimed in [either of claims 20 and] claim 21,

b) the activator is prepared or isolated by known chemical processes, and

c) physiologically acceptable additives are added to the activator.